Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Newron Pharmaceuticals S.p.A.. (5/25/16). "Press Release: Newron Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference in New York". Milan.

Organisations Organisation Newron Pharmaceuticals S.p.A. (SIX: NWRN)
  Group Newron (Group)
  Organisation 2 Jefferies (Group)
  Today Leucadia (Group)
  Group Leucadia (Group)
Products Product Jefferies 2016 Global Healthcare Conference New York
  Product 2 Xadago®
Index term Index term Newron–Leucadia: investor conference, 201606 supply service Newron presents at Jefferies 2016 Global Healthcare Conference NY
Persons Person Weber, Stefan (Newron Pharmaceuticals 201504 CEO before CFO)
  Person 2 Phillips, Julia (FTI Consulting 201110)
     


Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced that Stefan Weber, CEO, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Tuesday, June 7, 2016 at 3:00 p.m. ET.

The Jefferies Healthcare Conference features an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors. The conference addresses investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.


About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Xadago® (Safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the US. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing NW-3509 as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

For more information, please visit: www.newron.com


For more information

Media
Investors and analysts
Stefan Weber - CEO
Phone: +39 02 6103 46 26
E-mail: pr@newron.com
UK/Europe
Julia Phillips
FTI Consulting
Phone: +44 (0)20 3727 1000
Switzerland
Martin Meier-Pfister
IRF Communications
Phone: +41 43 244 81 40
Germany
Anne Hennecke
MC Services AG
Phone: +49 211 52925222
anne.hennecke@mc-services.eu
U.S.
Alison Chen
LaVoieHealthScience
Phone: +1 617 374 8800, Ext. 104
achen@lavoiehealthscience.com
Stefan Weber – CEO
Phone: +39 02 6103 46 30
E-mail: ir@newron.com
UK/Europe
Julia Phillips
FTI Consulting
Phone: +44 (0)20 3727 1000
Switzerland
Martin Meier-Pfister
IRF Communications
Phone: +41 43 244 81 40
Germany
Anne Hennecke
MC Services AG
Phone: +49 211 52925222
anne.hennecke@mc-services.eu
U.S.
Beth Kurth
LaVoieHealthScience Phone: +1 617 374 8800, Ext. 106
bkurth@lavoiehealthscience.com

   
Record changed: 2017-07-02

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for Newron (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px